STAT Plus: California scolds McKesson for supplying excessive controlled substances to a children’s pharmacy
The California Board of Pharmacy is accusing McKesson (MCK), the large pharmaceutical wholesaler, of selling…
Category: STAT Plus
Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share…
STAT Plus: A closer look at Bernie Sanders’ plans to upend pharma and lower drug prices
The following is an excerpt from STAT’s deep dive report into the Democrats running for…
STAT Plus: Pharmalittle: Novartis lottery for gene therapy begins amid tough questions; coronavirus vaccine may take a year
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT Plus: U.S. officials lash out at the Dutch government for moves that ‘undermine’ pharma patent rights
In an unusual move, the U.S. Embassy in the Netherlands is taking the Dutch government…
STAT Plus: Beam Therapeutics raises $180 million in IPO
Beam Therapeutics (BEAM), a Cambridge, Mass., genome-editing startup, raised $180 million in an initial public…
STAT Plus: Pharmalittle: Buttigieg wants pharma to ‘thrive’; U.S. patent panel boosts Biogen, disappoints Gilead
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: Big Tech aimed to disrupt health care. Big Retail may be better positioned to do so
Move aside, Big Tech. If 2017 was the year technology giants like Apple set their…
Sanofi reports positive results on multiple sclerosis drug licensed from Principia
The French drug giant Sanofi on Thursday reported positive results in a study of its…
STAT Plus: Years later, raw clinical trial data tells us the extent of Avandia’s heart risks
File this under “What a difference patient-level data can make.” In 2007, controversy flared over…
STAT Plus: A closer look at Pete Buttigieg’s aggressive, wonky plan to lower drug prices
The following is an excerpt from STAT’s deep dive report into the Democrats running for…
STAT Plus: Gilead loses its challenge to a pair of U.S. patents over an HIV prevention pill
In a setback to Gilead Sciences (GILD), a federal panel rejected its bid to invalidate…
STAT Plus: Pharmalittle: Trump claims on drug prices are mostly false; Merck to spin off old drugs into new company
Good morning, everyone, and welcome to the middle of the week, which arrived rather quickly,…
STAT Plus: New ‘real world evidence’ company leverages medical societies to produce data for pharma
Two years ago, Roche spent $1.9 billion to buy a startup, Flatiron Health, which uses…
STAT Plus: This biotech just bought three failed drugs. Here’s why
Biopharma companies don’t usually buy experimental drugs that don’t work. But that’s exactly what CODA…
STAT Plus: 4 ways Walmart is hoping its retail savvy can overhaul the health care system
Walmart made waves in September when it announced an ambitious plan to create new, freestanding…
STAT Plus: A former Taro Pharma executive is indicted in generic price-fixing probe
A former senior executive at Taro Pharmaceuticals USA was indicted for his role in a…
STAT Plus: Pharma execs argue new Canadian regulations for setting drug prices will hurt the country
As Canada gets set to implement new regulations designed to cut prescription drug spending, the…
STAT Plus: FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake
As frustration mounts over the slower-than-expected uptake of biosimilars in the marketplace, two U.S. federal…
STAT Plus: Pharmalittle: France indicts Sanofi over epilepsy drug risks; Trump talk of drug pricing in SOTU speech may backfire
Hello, everyone, and how are you today? We are doing just fine, thank you, despite…
STAT Plus: This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund
Marc Andreessen, famous for proclaiming that software was “eating the world,” said in 2009 that…
STAT Plus: If Medicare negotiated insulin prices like the VA, it could have saved billions
As insulin becomes a poster child for the growing outcry over the cost of medicines,…
STAT Plus: Pharmalittle: FDA approves peanut allergy drug; employer coalition likes House drug pricing bill
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: FDA approves the first treatment for peanut allergy, but commercial success is hardly assured
Children and teenagers with severe, sometimes life-threatening peanut allergies can reduce their risk from accidental…
.jpg)
STAT Plus: Employers shoulder plenty of drug costs, but haven’t lobbied much to lower them — until now
WASHINGTON — Companies like Pepsi, Walmart, and Jack in the Box foot the bill for…
STAT Plus: Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?
What’s Gilead going to buy? That’s the single, persistent question Daniel O’Day has faced in…
STAT Plus: European regulators could take a harder line on the review of an Agios blood cancer drug
A European regulatory setback for a Bristol-Myers Squibb (BMY) blood-cancer drug could have a negative…
STAT Plus: PBMs favor their own pharmacies in the Florida Medicaid program
As angst rises over the prices paid for medicines, a new analysis finds some pharmacy…
STAT Plus: Pharmalittle: Trump gives states a tool to lower drug costs, with a catch; ICER updates how it assesses drugs
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Trump’s Medicaid changes offers states new powers to lower drug costs — with a catch
WASHINGTON — The Trump administration on Thursday unveiled a powerful new tool for states to…
STAT Plus: ‘It’s very easy to get starry-eyed about AI’: Experts offer warnings on digital disruption in health care
Jenni West’s job is to spot innovative technology that improves people’s lives. As associate director…
STAT Plus: U.S. officials will let Novartis pay expenses for some Kymriah patients who must travel for treatment
In an unexpected move, the Department of Health and Human Services will allow Novartis (NVS)…
STAT Plus: As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking
There are few things in this world more squishy than Wonder Bread. Exception: Biogen’s answers…
STAT Plus: Most innovative cancer drugs take too long to reach patients in the U.K.
Despite giddy advances in treating cancer, a new analysis finds needed medicines have been reaching…
STAT Plus: Pharmalittle: Drug prices forecast to rise 3.6%; House committee considers bill to update generic labels
Rise and shine, everyone, another busy day is on the way. Our short person has…
STAT Plus: Medical data startup Syapse cuts 10% of workforce as it prioritizes data analytics and insights
SAN FRANCISCO — Syapse, among the highest profile companies in a wave of startups seeking…
STAT Plus: Spring Bank scraps hepatitis R&D after patient dies in trial
Spring Bank Pharmaceuticals (SBPH) said Wednesday it was abandoning efforts to develop a drug to…
STAT Plus: Pharmalittle: Novartis says coronavirus not disrupting supply chain, for now; FDA releases new gene therapy policies
Good morning, everyone, and welcome to the middle of the week. You made it this…
STAT Plus: In a pivot, Decibel Therapeutics loses its founding CEO — and some of its discovery programs
Decibel Therapeutics CEO Steven Holtzman is really, officially retiring. The departure of the longtime vet…
STAT Plus: The FDA wants to know how Instagram influencers sway patient views on medicines
In 2015, Kim Kardashian promoted a morning-sickness pill to her millions of followers on social…
STAT Plus: With new rules, FDA aims to spark competition, lower prices for expensive gene therapies
WASHINGTON — The Food and Drug Administration released a slew of gene therapy policies Tuesday…
STAT Plus: Prosecutors identified ‘Pharma Co. X’ as central to alleged opioid kickback scheme. Was it Purdue?
Federal prosecutors this week announced a $145 million settlement with an electronic health records company…
STAT Plus: Biotech earnings preview: Unsettled investors hoping for strong 2020 outlooks
Biotech earnings season kicks off Thursday with fourth-quarter reports from Alexion Pharma (ALXN), Amgen (AMGN),…
STAT Plus: Pharmalittle: Insulin dominates Democrats’ health agenda in Iowa; FDA studies Instagram influencers
Good morning, everyone. The world is watching China, the new coronavirus, and the outbreak’s spread….
STAT Plus: Acceleron pulmonary hypertension drug succeeds in mid-stage clinical trial
Acceleron Pharma said Monday that a mid-stage clinical trial involving an experimental drug for pulmonary…
STAT Plus: Big drug purchasers predict price hikes driven by expensive new therapies
More than two dozen big buyers of prescription medicines expect that prices will rise by…
STAT Plus: McKesson reaches $175 million deal with shareholders over lax oversight of opioid shipments
As pressure mounts on pharmaceutical wholesalers over their role in the opioid crisis, McKesson (MCK)…
STAT Plus: McKesson reaches $175 million deal with shareholders over lax oversight of opioid shipments
As pressure mounts on pharmaceutical wholesalers over their role in the opioid crisis, McKesson (MCK)…
STAT Plus: Roche is fined by Romania for thwarting competition to its cancer medicines
Following a two-year investigation, Roche (RHHBY) was fined $14 million by antitrust authorities in Romania…
STAT Plus: The suburbs are cheaper, but they don’t have what Kendall Square has for biotechs: serendipity
You know Kendall Square’s office rents have gotten stratospheric when a CEO compares the neighborhood…